Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for Prevention of Paclitaxel-induced Peripheral Neuropathy
NCT06135493Phase 2Completed
- Sponsor
- Future University in Egypt
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of losartan in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Future University in Egypt. Primary endpoint: Development of paclitaxel-induced peripheral neuropathy at 12 weeks. Started Dec 2023; status: completed.
02
Drugs
losartan
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT06135493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06135493.